Review



anti cd8a  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Bio X Cell anti cd8a
    Anti Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 641 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd8a/InVivoMAb+anti-mouse+CD8%CE%B1/pm42875546-459-7-8
    Average 97 stars, based on 641 article reviews
    anti cd8a - by Bioz Stars, 2026-10
    97/100 stars

    Images

    Related Articles

    Mouse Assay:

    Article Title: Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy.
    Article Snippet: After 72 h of activation, CD8+ T cell culture supernatants were collected, stored at −20 °C and quantified using mouse TNF ELISA (R&D systems, MTA00B). .. Mice were intraperitoneally injected with 200 μg anti-CD8a (Bio X Cell, BE0061, RRID: AB_1125541), anti-CXCR3 (Bio X Cell, BE0249, RRID: AB_2687730), rat IgG2b isotype control (Bio X Cell, BE0090, RRID: AB_1107780) or Armenian hamster IgG isotype control (Bio X Cell, BE0091, RRID: AB_1107773) six times, on days −1, 1, 5, 9, 13 and 16 relative to subcutaneous tumor injection (day 0). ..

    Injection:

    Article Title: Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy.
    Article Snippet: After 72 h of activation, CD8+ T cell culture supernatants were collected, stored at −20 °C and quantified using mouse TNF ELISA (R&D systems, MTA00B). .. Mice were intraperitoneally injected with 200 μg anti-CD8a (Bio X Cell, BE0061, RRID: AB_1125541), anti-CXCR3 (Bio X Cell, BE0249, RRID: AB_2687730), rat IgG2b isotype control (Bio X Cell, BE0090, RRID: AB_1107780) or Armenian hamster IgG isotype control (Bio X Cell, BE0091, RRID: AB_1107773) six times, on days −1, 1, 5, 9, 13 and 16 relative to subcutaneous tumor injection (day 0). ..

    Article Title: Deficiency of lysosomal TMEM175 in myeloid macrophages exerts anti-tumor immunity via inflammasome and cross-presentation pathway
    Article Snippet: For clodronate liposomes treatment, mice were intravenously injected with the clodronate liposomes (YEASEN Biotechnology, 40337ES08) or control liposomes (YEASEN Biotechnology, 40338ES08) at a dose of 1 mg/20 g body weight at day −1, 6, and 13. .. For anti-CD8a (Bio X Cell, BE0061), anti-IL-1β (Bio X Cell, BE0246), and anti-IL-18 (Bio X Cell, BE0237) treatment, mice were intraperitoneally injected with 100 μg/100 μL antibody or isotype control (rat IgG2b isotype (Bio X Cell, BE0090) for anti-CD8a, Armenian hamster IgG isotype (Bio X Cell, BE0091) for anti-IL-1β, and rat IgG2a isotype (Bio X Cell, BE0089) for anti-IL-18) diluted with saline at day −1, 6, and 13. .. For CA-074 and BAPTA-AM treatment, mice were intratumorally injected with CA-074 (MCE, HY-103350) or BAPTA-AM (MCE, HY-100545) or vehicle (containing 10% DMSO, 40% PEG400, and 50% saline) at a dose of 200 μg/20 g body weight at days 7, 10, and 13.

    Article Title: Thymopentin enhances adenoviral oncolytic therapy by regulating macrophages and CD8 + T cells.
    Article Snippet: .. For macrophage and CD8+ T-cell depletion, BALB/c mice were intraperitoneally injected with 500 μg of anti-CD8a (Bioxcell, West Lebanon, NH, USA) or anti-CSF1R (Bioxcell, West Lebanon, NH, USA) antibodies every other day for a total of three injections. .. For the PBMC-humanized CDX model, exponentially growing MDA-MB-231 and/or HepG2 cells were harvested and then injected subcutaneously into the flanks of NCG mice (GemPharmatech, NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt) on day 0.

    Article Title: The high protection of a novel chemo-attenuated sporozoite vaccine requires IL-15-mediated liver CD8 + tissue-resident memory T-cell responses.
    Article Snippet: .. In vivo depletion assay To deplete CD4+ or CD8+ T cells, immunized mice were i.p. injected with 200 μg of either anti-CD4 (clone GK1.5; BioXCell), anti-CD8a (clone YTS 169.4; BioXCell), or the corresponding isotype control IgG 1 day prior to and on the day of the challenge. ..

    Control:

    Article Title: Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy.
    Article Snippet: After 72 h of activation, CD8+ T cell culture supernatants were collected, stored at −20 °C and quantified using mouse TNF ELISA (R&D systems, MTA00B). .. Mice were intraperitoneally injected with 200 μg anti-CD8a (Bio X Cell, BE0061, RRID: AB_1125541), anti-CXCR3 (Bio X Cell, BE0249, RRID: AB_2687730), rat IgG2b isotype control (Bio X Cell, BE0090, RRID: AB_1107780) or Armenian hamster IgG isotype control (Bio X Cell, BE0091, RRID: AB_1107773) six times, on days −1, 1, 5, 9, 13 and 16 relative to subcutaneous tumor injection (day 0). ..

    Article Title: Deficiency of lysosomal TMEM175 in myeloid macrophages exerts anti-tumor immunity via inflammasome and cross-presentation pathway
    Article Snippet: For clodronate liposomes treatment, mice were intravenously injected with the clodronate liposomes (YEASEN Biotechnology, 40337ES08) or control liposomes (YEASEN Biotechnology, 40338ES08) at a dose of 1 mg/20 g body weight at day −1, 6, and 13. .. For anti-CD8a (Bio X Cell, BE0061), anti-IL-1β (Bio X Cell, BE0246), and anti-IL-18 (Bio X Cell, BE0237) treatment, mice were intraperitoneally injected with 100 μg/100 μL antibody or isotype control (rat IgG2b isotype (Bio X Cell, BE0090) for anti-CD8a, Armenian hamster IgG isotype (Bio X Cell, BE0091) for anti-IL-1β, and rat IgG2a isotype (Bio X Cell, BE0089) for anti-IL-18) diluted with saline at day −1, 6, and 13. .. For CA-074 and BAPTA-AM treatment, mice were intratumorally injected with CA-074 (MCE, HY-103350) or BAPTA-AM (MCE, HY-100545) or vehicle (containing 10% DMSO, 40% PEG400, and 50% saline) at a dose of 200 μg/20 g body weight at days 7, 10, and 13.

    Article Title: Peritumoural adipose tissue promotes ferroptosis resistance by 3-hydroxykynurenine-mediated suppression of ferritinophagy.
    Article Snippet: .. Antibody-mediated CD8+ T cell depletion For CD8+ T cell depletion in the iWAT model, C57BL/6J mice were administered six intraperitoneal injections of anti-CD8a (BioXCell) or isotype Nature Cell Biology Article https://doi.org/10.1038/s41556-026-01907-x control (BioXCell). ..

    Article Title: The high protection of a novel chemo-attenuated sporozoite vaccine requires IL-15-mediated liver CD8 + tissue-resident memory T-cell responses.
    Article Snippet: .. In vivo depletion assay To deplete CD4+ or CD8+ T cells, immunized mice were i.p. injected with 200 μg of either anti-CD4 (clone GK1.5; BioXCell), anti-CD8a (clone YTS 169.4; BioXCell), or the corresponding isotype control IgG 1 day prior to and on the day of the challenge. ..

    Article Title: The metabolic reprogramming of T cells controls airway remodeling in severe asthma
    Article Snippet: For LIGHT-induction, mice were given 10ug recombinant mouse LIGHT (R&D) or PBS intratracheally for two consecutive days and sacrificed on day 3. .. For T cell depletion, 100ug anti-CD4 (GK1.5; BioXCell) and 100ug anti-CD8a (YTS 169.4; BioXCell) or matching isotype control (LTF-2 Rat IgG2b; BioXCell) were given i.p. beginning on day 0 prior to HDM induction and continuing every other day until the end of the experiment for a total of 10 doses. ..

    Saline:

    Article Title: Deficiency of lysosomal TMEM175 in myeloid macrophages exerts anti-tumor immunity via inflammasome and cross-presentation pathway
    Article Snippet: For clodronate liposomes treatment, mice were intravenously injected with the clodronate liposomes (YEASEN Biotechnology, 40337ES08) or control liposomes (YEASEN Biotechnology, 40338ES08) at a dose of 1 mg/20 g body weight at day −1, 6, and 13. .. For anti-CD8a (Bio X Cell, BE0061), anti-IL-1β (Bio X Cell, BE0246), and anti-IL-18 (Bio X Cell, BE0237) treatment, mice were intraperitoneally injected with 100 μg/100 μL antibody or isotype control (rat IgG2b isotype (Bio X Cell, BE0090) for anti-CD8a, Armenian hamster IgG isotype (Bio X Cell, BE0091) for anti-IL-1β, and rat IgG2a isotype (Bio X Cell, BE0089) for anti-IL-18) diluted with saline at day −1, 6, and 13. .. For CA-074 and BAPTA-AM treatment, mice were intratumorally injected with CA-074 (MCE, HY-103350) or BAPTA-AM (MCE, HY-100545) or vehicle (containing 10% DMSO, 40% PEG400, and 50% saline) at a dose of 200 μg/20 g body weight at days 7, 10, and 13.

    In Vivo:

    Article Title: The high protection of a novel chemo-attenuated sporozoite vaccine requires IL-15-mediated liver CD8 + tissue-resident memory T-cell responses.
    Article Snippet: .. In vivo depletion assay To deplete CD4+ or CD8+ T cells, immunized mice were i.p. injected with 200 μg of either anti-CD4 (clone GK1.5; BioXCell), anti-CD8a (clone YTS 169.4; BioXCell), or the corresponding isotype control IgG 1 day prior to and on the day of the challenge. ..

    Depletion Assay:

    Article Title: The high protection of a novel chemo-attenuated sporozoite vaccine requires IL-15-mediated liver CD8 + tissue-resident memory T-cell responses.
    Article Snippet: .. In vivo depletion assay To deplete CD4+ or CD8+ T cells, immunized mice were i.p. injected with 200 μg of either anti-CD4 (clone GK1.5; BioXCell), anti-CD8a (clone YTS 169.4; BioXCell), or the corresponding isotype control IgG 1 day prior to and on the day of the challenge. ..

    other:

    Article Title: Deficiency of lysosomal TMEM175 in myeloid macrophages exerts anti-tumor immunity via inflammasome and cross-presentation pathway.
    Article Snippet: For clodronate liposomes treatment, mice were intravenously injected with the clodronate liposomes (YEASEN Biotechnology, 40337ES08) or control liposomes (YEASEN Biotechnology, 40338ES08) at a dose of 1 mg/20 g body weight at day -1, 6, and 13.



    Similar Products

    94
    Miltenyi Biotec cd8αpe
    Cd8αpe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd8a/CD8a+Antibody%2C+anti-mouse%2C+REAfinity/10__1038_slash_s41398___026___04497___2-166-30-31
    Average 94 stars, based on 1 article reviews
    cd8αpe - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    Cytek Biosciences anti cd8a
    Anti Cd8a, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd8a/PE-Cyanine7+Anti-Human+CD8a/pm42880242-230-60-63
    Average 93 stars, based on 1 article reviews
    anti cd8a - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    97
    Bio X Cell anti cd8a
    Anti Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd8a/InVivoMAb+anti-mouse+CD8%CE%B1/pm42875546-459-7-8
    Average 97 stars, based on 1 article reviews
    anti cd8a - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    97
    Bio X Cell anti mouse cd8a
    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus <t>anti-CD8a</t> antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.
    Anti Mouse Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd8a/InVivoMAb+anti-mouse+CD8%CE%B1/pmc13628106-246-7-9
    Average 97 stars, based on 1 article reviews
    anti mouse cd8a - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    93
    Proteintech gb21303 apc anti mouse cd8a antibody proteintech
    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus <t>anti-CD8a</t> antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.
    Gb21303 Apc Anti Mouse Cd8a Antibody Proteintech, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd8a/APC+Anti-mouse+CD8a/pm42810343-283-261-266
    Average 93 stars, based on 1 article reviews
    gb21303 apc anti mouse cd8a antibody proteintech - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    91
    Cytek Biosciences cd8a
    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus <t>anti-CD8a</t> antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.
    Cd8a, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd8a/APC+Anti-Human+CD8a/10__1021_slash_acsnano__6c11865-448-42-46
    Average 91 stars, based on 1 article reviews
    cd8a - by Bioz Stars, 2026-10
    91/100 stars
      Buy from Supplier

    93
    Proteintech pe anti mouse cd8
    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus <t>anti-CD8a</t> antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.
    Pe Anti Mouse Cd8, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd8a/PE+Anti-mouse+CD8a/pm42785880-55-14-21
    Average 93 stars, based on 1 article reviews
    pe anti mouse cd8 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    95
    Elabscience Biotechnology pe anti mouse cd8 alpha antibody
    Overexpression of UPF1 in ccRCC inhibits M2 macrophage polarization and enhances the tumor suppressor function of <t>CD8</t> + T cells, Caki-1 cell groups of sh-NC+PBS, sh-UPF1+PBS, or sh-UPF1 + 2-DG, and the conditioned medium was used to culture and polarize M0 macrophages. The polarized macrophages were cultured with activated CD8 + T cells. (A) CFSE assessed CD8 + T cell proliferative capacity. (B) Flow cytometry measured apoptosis rate of CD8 + T cells in different co-culture systems. (C) CD8 + T cells from culture systems were co-cultured with normal Caki-1 cells, with LDH assays determining cytotoxic effect of CD8 + T cells. *, p < 0.05. cRCC, Clear cell renal cell carcinoma; UPF1, Up-frameshift protein 1; 2-DG, 2-Deoxy-D-glucose; CFSE, Carboxyfluorescein succinimidyl ester.
    Pe Anti Mouse Cd8 Alpha Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd8a/PE+Anti-Mouse+CD8a+Antibody/pmc13642288-120-47-53
    Average 95 stars, based on 1 article reviews
    pe anti mouse cd8 alpha antibody - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    95
    ABclonal Biotechnology fluorescein isothiocyanate anti human cd8a
    Overexpression of UPF1 in ccRCC inhibits M2 macrophage polarization and enhances the tumor suppressor function of <t>CD8</t> + T cells, Caki-1 cell groups of sh-NC+PBS, sh-UPF1+PBS, or sh-UPF1 + 2-DG, and the conditioned medium was used to culture and polarize M0 macrophages. The polarized macrophages were cultured with activated CD8 + T cells. (A) CFSE assessed CD8 + T cell proliferative capacity. (B) Flow cytometry measured apoptosis rate of CD8 + T cells in different co-culture systems. (C) CD8 + T cells from culture systems were co-cultured with normal Caki-1 cells, with LDH assays determining cytotoxic effect of CD8 + T cells. *, p < 0.05. cRCC, Clear cell renal cell carcinoma; UPF1, Up-frameshift protein 1; 2-DG, 2-Deoxy-D-glucose; CFSE, Carboxyfluorescein succinimidyl ester.
    Fluorescein Isothiocyanate Anti Human Cd8a, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd8a/CD8A+Rabbit+pAb/pmc13557068-235-21-25
    Average 95 stars, based on 1 article reviews
    fluorescein isothiocyanate anti human cd8a - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    Image Search Results


    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus anti-CD8a antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.

    Journal: Cancer Discovery

    Article Title: Senescent-Like Neutrophils Shape Angiogenic Immunosuppressive Niches in Colorectal Cancer Liver Metastasis

    doi: 10.1158/2159-8290.CD-25-0820

    Figure Lengend Snippet: Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus anti-CD8a antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.

    Article Snippet: For CD8 + T-cell depletion, 200 μg anti-mouse CD8a (Bio X Cell, BE0061, RRID: AB_1125541) was injected intraperitoneally twice a week.

    Techniques: Comparison, Expressing, Staining, Analysis, Migration, Control

    Overexpression of UPF1 in ccRCC inhibits M2 macrophage polarization and enhances the tumor suppressor function of CD8 + T cells, Caki-1 cell groups of sh-NC+PBS, sh-UPF1+PBS, or sh-UPF1 + 2-DG, and the conditioned medium was used to culture and polarize M0 macrophages. The polarized macrophages were cultured with activated CD8 + T cells. (A) CFSE assessed CD8 + T cell proliferative capacity. (B) Flow cytometry measured apoptosis rate of CD8 + T cells in different co-culture systems. (C) CD8 + T cells from culture systems were co-cultured with normal Caki-1 cells, with LDH assays determining cytotoxic effect of CD8 + T cells. *, p < 0.05. cRCC, Clear cell renal cell carcinoma; UPF1, Up-frameshift protein 1; 2-DG, 2-Deoxy-D-glucose; CFSE, Carboxyfluorescein succinimidyl ester.

    Journal: Frontiers in Immunology

    Article Title: UPF1-dependent glycolysis driven by LINC00887 facilitates macrophage M2 polarization in clear cell renal cell carcinoma

    doi: 10.3389/fimmu.2026.1833383

    Figure Lengend Snippet: Overexpression of UPF1 in ccRCC inhibits M2 macrophage polarization and enhances the tumor suppressor function of CD8 + T cells, Caki-1 cell groups of sh-NC+PBS, sh-UPF1+PBS, or sh-UPF1 + 2-DG, and the conditioned medium was used to culture and polarize M0 macrophages. The polarized macrophages were cultured with activated CD8 + T cells. (A) CFSE assessed CD8 + T cell proliferative capacity. (B) Flow cytometry measured apoptosis rate of CD8 + T cells in different co-culture systems. (C) CD8 + T cells from culture systems were co-cultured with normal Caki-1 cells, with LDH assays determining cytotoxic effect of CD8 + T cells. *, p < 0.05. cRCC, Clear cell renal cell carcinoma; UPF1, Up-frameshift protein 1; 2-DG, 2-Deoxy-D-glucose; CFSE, Carboxyfluorescein succinimidyl ester.

    Article Snippet: Antibodies included: FITC Mouse monoclonal to CD68 (ab134351, abcam, UK), Pacific Blue anti-human CD86 Antibody (305417, yajimall, China), CD206 (MMR) Monoclonal Antibody (19.2)-PE (12-2069-42, ThermoFisher, USA), PerCP/Cyanine5.5 Anti-Mouse F4/80 Antibody (E-AB-F0995J, Elabscience, China), PE Anti-CD206 mouse antibody (E-AB-F1135D, Elabscience, China), APC Anti-mouse CD3 antibody (E-AB-F1013E, Elabscience, China), PE Anti-mouse CD8 alpha antibody (E-AB-F1104D, Elabscience, China).

    Techniques: Over Expression, Cell Culture, Flow Cytometry, Co-culture Assay

    LINC00887/UPF1-mediated aerobic glycolysis leads to lactic acid accumulation and facilitates immune evasion in ccRCC in vivo , A syngeneic tumor model was developed by injecting BALB/c mice with Renca cells expressing sh-NC or sh-LINC00887, followed by treatment with sh-NC or sh-UPF1 lentivirus. A-C: Assessment of tumor size (A) , volume (B) , and weight (C) . (D, E) qRT-PCR analyses for LINC00887 (D) and UPF1 (E) mRNA levels. (F) IHC analysis for UPF1, LDH-A, KI67 protein levels. (G) Kit assay for lactate levels in tumors. (H) Proportion of M2 macrophages (F4/80+CD206+) by flow cytometry. (I) Immunofluorescence assay for CD206+ macrophages. (J) Proportion of CD8 + T cells (CD3 + CD8 + ) in tumor tissues. ns, no significant difference. * p < 0.05. cRCC, Clear cell renal cell carcinoma; UPF1, Up-frameshift protein 1; LDH-A, Lactate dehydrogenase A; CD206, Mannose receptor C-type 1; CD3, Cluster of differentiation 3; CD8, Cluster of differentiation 8.

    Journal: Frontiers in Immunology

    Article Title: UPF1-dependent glycolysis driven by LINC00887 facilitates macrophage M2 polarization in clear cell renal cell carcinoma

    doi: 10.3389/fimmu.2026.1833383

    Figure Lengend Snippet: LINC00887/UPF1-mediated aerobic glycolysis leads to lactic acid accumulation and facilitates immune evasion in ccRCC in vivo , A syngeneic tumor model was developed by injecting BALB/c mice with Renca cells expressing sh-NC or sh-LINC00887, followed by treatment with sh-NC or sh-UPF1 lentivirus. A-C: Assessment of tumor size (A) , volume (B) , and weight (C) . (D, E) qRT-PCR analyses for LINC00887 (D) and UPF1 (E) mRNA levels. (F) IHC analysis for UPF1, LDH-A, KI67 protein levels. (G) Kit assay for lactate levels in tumors. (H) Proportion of M2 macrophages (F4/80+CD206+) by flow cytometry. (I) Immunofluorescence assay for CD206+ macrophages. (J) Proportion of CD8 + T cells (CD3 + CD8 + ) in tumor tissues. ns, no significant difference. * p < 0.05. cRCC, Clear cell renal cell carcinoma; UPF1, Up-frameshift protein 1; LDH-A, Lactate dehydrogenase A; CD206, Mannose receptor C-type 1; CD3, Cluster of differentiation 3; CD8, Cluster of differentiation 8.

    Article Snippet: Antibodies included: FITC Mouse monoclonal to CD68 (ab134351, abcam, UK), Pacific Blue anti-human CD86 Antibody (305417, yajimall, China), CD206 (MMR) Monoclonal Antibody (19.2)-PE (12-2069-42, ThermoFisher, USA), PerCP/Cyanine5.5 Anti-Mouse F4/80 Antibody (E-AB-F0995J, Elabscience, China), PE Anti-CD206 mouse antibody (E-AB-F1135D, Elabscience, China), APC Anti-mouse CD3 antibody (E-AB-F1013E, Elabscience, China), PE Anti-mouse CD8 alpha antibody (E-AB-F1104D, Elabscience, China).

    Techniques: In Vivo, Expressing, Quantitative RT-PCR, Analysis, Flow Cytometry, Immunofluorescence